![[-]](https://www.aiowares.com/images/collapse.png "[-]")
02-23-2026, 10:34 PM
Novo Nordisk’s Wegovy Weight Loss Shot Approved at Higher Dose in EU
Regulatory applications are pending with the U.S. Food and Drug Administration
Novo Nordisk received final approval for a higher dose of its Wegovy weight-loss shot from the European Commission.
Approval of the higher 7.2 milligram dose of Wegovy means that doctors in the EU can now prescribe three 2.4 milligram injections in one sitting, once a week.
“This gives doctors another option to help adults who need more weight loss after being on the 2.4 milligram dose,” the Danish drugmaker said.
The decision announced Tuesday means that adults with obesity in all 27 European countries can now take the 2.4 milligram dose of Wegovy for at least four weeks and then move up to 7.2 milligrams if they need greater weight loss, Novo Nordisk said.
In a study of adults with obesity but without diabetes, patients taking a 7.2 milligram dose of Wegovy over about a year and a half lost 21% of their body weight on average, while around one in three people lost 25% or more of their body weight.
The EU decision follows approval of the higher dose by British authorities last month, while regulatory applications are pending with the U.S. Food and Drug Administration and several other countries.
Novo Nordisk has applied for approval of a 7.2 milligram single-dose pen in the EU, and if approved, it could be available this year.
Regulatory applications are pending with the U.S. Food and Drug Administration
Novo Nordisk received final approval for a higher dose of its Wegovy weight-loss shot from the European Commission.
Approval of the higher 7.2 milligram dose of Wegovy means that doctors in the EU can now prescribe three 2.4 milligram injections in one sitting, once a week.
“This gives doctors another option to help adults who need more weight loss after being on the 2.4 milligram dose,” the Danish drugmaker said.
The decision announced Tuesday means that adults with obesity in all 27 European countries can now take the 2.4 milligram dose of Wegovy for at least four weeks and then move up to 7.2 milligrams if they need greater weight loss, Novo Nordisk said.
In a study of adults with obesity but without diabetes, patients taking a 7.2 milligram dose of Wegovy over about a year and a half lost 21% of their body weight on average, while around one in three people lost 25% or more of their body weight.
The EU decision follows approval of the higher dose by British authorities last month, while regulatory applications are pending with the U.S. Food and Drug Administration and several other countries.
Novo Nordisk has applied for approval of a 7.2 milligram single-dose pen in the EU, and if approved, it could be available this year.
